Aberrant activation of the androgen receptor by NF-κB2/p52 in prostate cancer cells

Nagalakshmi Nadiminty, Wei Lou, Meng Sun, Jun Chen, Jiao Yue, Hsing Jien Kung, Christopher P. Evans, Qinghua Zhou, Allen C. Gao

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Prostate cancer initiation and progression are uniquely dependent on the androgen receptor (AR). Even when the cancer progresses to a castration-resistant stage, AR signaling remains active via a variety of mechanisms. In the present study, we showed that NF-κB/p52 can activate the AR, resulting in increased transactivation of AR-responsive genes, such as PSA and NKX3.1, in a ligand-independent manner. NF-κB2/p52 enhances nuclear translocation and activation of AR by interacting with its NH 2-terminal domain and enhances the recruitment of coactivators such as p300 to the promoters of AR-dependent genes. These results were confirmed in three different prostate cancer cell lines: LAPC-4 (wild-type AR), LNCaP (mutant AR), and C4-2 (castration resistant). Transfection of p52 into LAPC-4 and LNCaP cells (which express low levels of p52) showed increased activation of the endogenous AR. Downregulation of endogenous p52 in C4-2 cells resulted in abrogation of AR constitutive activation. Comparison of the relative effects of p52 and p65 (RelA) showed that p52, but not p65, could activate the AR. Collectively, these findings, together with previous reports that the levels of NF-κB2/p52 are elevated in prostate cancer cells and that active NF-κB2/p52 promotes prostate cancer cell growth in vitro and in vivo, suggest that NF-κB2/p52 may play a critical role in the progression of castration-resistant prostate cancer.

Original languageEnglish
Pages (from-to)3309-3319
Number of pages11
JournalCancer Research
Volume70
Issue number8
DOIs
Publication statusPublished - Apr 15 2010
Externally publishedYes

Fingerprint

Androgen Receptors
Prostatic Neoplasms
Castration
Transcriptional Activation
Genes
Transfection
Down-Regulation
Ligands
Cell Line

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Aberrant activation of the androgen receptor by NF-κB2/p52 in prostate cancer cells. / Nadiminty, Nagalakshmi; Lou, Wei; Sun, Meng; Chen, Jun; Yue, Jiao; Kung, Hsing Jien; Evans, Christopher P.; Zhou, Qinghua; Gao, Allen C.

In: Cancer Research, Vol. 70, No. 8, 15.04.2010, p. 3309-3319.

Research output: Contribution to journalArticle

Nadiminty, N, Lou, W, Sun, M, Chen, J, Yue, J, Kung, HJ, Evans, CP, Zhou, Q & Gao, AC 2010, 'Aberrant activation of the androgen receptor by NF-κB2/p52 in prostate cancer cells', Cancer Research, vol. 70, no. 8, pp. 3309-3319. https://doi.org/10.1158/0008-5472.CAN-09-3703
Nadiminty, Nagalakshmi ; Lou, Wei ; Sun, Meng ; Chen, Jun ; Yue, Jiao ; Kung, Hsing Jien ; Evans, Christopher P. ; Zhou, Qinghua ; Gao, Allen C. / Aberrant activation of the androgen receptor by NF-κB2/p52 in prostate cancer cells. In: Cancer Research. 2010 ; Vol. 70, No. 8. pp. 3309-3319.
@article{b17ac493dada4424ac7ab1af3c025539,
title = "Aberrant activation of the androgen receptor by NF-κB2/p52 in prostate cancer cells",
abstract = "Prostate cancer initiation and progression are uniquely dependent on the androgen receptor (AR). Even when the cancer progresses to a castration-resistant stage, AR signaling remains active via a variety of mechanisms. In the present study, we showed that NF-κB/p52 can activate the AR, resulting in increased transactivation of AR-responsive genes, such as PSA and NKX3.1, in a ligand-independent manner. NF-κB2/p52 enhances nuclear translocation and activation of AR by interacting with its NH 2-terminal domain and enhances the recruitment of coactivators such as p300 to the promoters of AR-dependent genes. These results were confirmed in three different prostate cancer cell lines: LAPC-4 (wild-type AR), LNCaP (mutant AR), and C4-2 (castration resistant). Transfection of p52 into LAPC-4 and LNCaP cells (which express low levels of p52) showed increased activation of the endogenous AR. Downregulation of endogenous p52 in C4-2 cells resulted in abrogation of AR constitutive activation. Comparison of the relative effects of p52 and p65 (RelA) showed that p52, but not p65, could activate the AR. Collectively, these findings, together with previous reports that the levels of NF-κB2/p52 are elevated in prostate cancer cells and that active NF-κB2/p52 promotes prostate cancer cell growth in vitro and in vivo, suggest that NF-κB2/p52 may play a critical role in the progression of castration-resistant prostate cancer.",
author = "Nagalakshmi Nadiminty and Wei Lou and Meng Sun and Jun Chen and Jiao Yue and Kung, {Hsing Jien} and Evans, {Christopher P.} and Qinghua Zhou and Gao, {Allen C.}",
year = "2010",
month = "4",
day = "15",
doi = "10.1158/0008-5472.CAN-09-3703",
language = "English",
volume = "70",
pages = "3309--3319",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Aberrant activation of the androgen receptor by NF-κB2/p52 in prostate cancer cells

AU - Nadiminty, Nagalakshmi

AU - Lou, Wei

AU - Sun, Meng

AU - Chen, Jun

AU - Yue, Jiao

AU - Kung, Hsing Jien

AU - Evans, Christopher P.

AU - Zhou, Qinghua

AU - Gao, Allen C.

PY - 2010/4/15

Y1 - 2010/4/15

N2 - Prostate cancer initiation and progression are uniquely dependent on the androgen receptor (AR). Even when the cancer progresses to a castration-resistant stage, AR signaling remains active via a variety of mechanisms. In the present study, we showed that NF-κB/p52 can activate the AR, resulting in increased transactivation of AR-responsive genes, such as PSA and NKX3.1, in a ligand-independent manner. NF-κB2/p52 enhances nuclear translocation and activation of AR by interacting with its NH 2-terminal domain and enhances the recruitment of coactivators such as p300 to the promoters of AR-dependent genes. These results were confirmed in three different prostate cancer cell lines: LAPC-4 (wild-type AR), LNCaP (mutant AR), and C4-2 (castration resistant). Transfection of p52 into LAPC-4 and LNCaP cells (which express low levels of p52) showed increased activation of the endogenous AR. Downregulation of endogenous p52 in C4-2 cells resulted in abrogation of AR constitutive activation. Comparison of the relative effects of p52 and p65 (RelA) showed that p52, but not p65, could activate the AR. Collectively, these findings, together with previous reports that the levels of NF-κB2/p52 are elevated in prostate cancer cells and that active NF-κB2/p52 promotes prostate cancer cell growth in vitro and in vivo, suggest that NF-κB2/p52 may play a critical role in the progression of castration-resistant prostate cancer.

AB - Prostate cancer initiation and progression are uniquely dependent on the androgen receptor (AR). Even when the cancer progresses to a castration-resistant stage, AR signaling remains active via a variety of mechanisms. In the present study, we showed that NF-κB/p52 can activate the AR, resulting in increased transactivation of AR-responsive genes, such as PSA and NKX3.1, in a ligand-independent manner. NF-κB2/p52 enhances nuclear translocation and activation of AR by interacting with its NH 2-terminal domain and enhances the recruitment of coactivators such as p300 to the promoters of AR-dependent genes. These results were confirmed in three different prostate cancer cell lines: LAPC-4 (wild-type AR), LNCaP (mutant AR), and C4-2 (castration resistant). Transfection of p52 into LAPC-4 and LNCaP cells (which express low levels of p52) showed increased activation of the endogenous AR. Downregulation of endogenous p52 in C4-2 cells resulted in abrogation of AR constitutive activation. Comparison of the relative effects of p52 and p65 (RelA) showed that p52, but not p65, could activate the AR. Collectively, these findings, together with previous reports that the levels of NF-κB2/p52 are elevated in prostate cancer cells and that active NF-κB2/p52 promotes prostate cancer cell growth in vitro and in vivo, suggest that NF-κB2/p52 may play a critical role in the progression of castration-resistant prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=77951036849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951036849&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-09-3703

DO - 10.1158/0008-5472.CAN-09-3703

M3 - Article

C2 - 20388792

AN - SCOPUS:77951036849

VL - 70

SP - 3309

EP - 3319

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 8

ER -